Esiai, Biogen's BAN2401 Alzheimer's hope approved for study in China



The Alzheimer’s disease drug candidate BAN2401, under co-development by US-based Biogen Inc., (Nasdaq: BIIB) and Eisai Co., Ltd, has won clinical trial approval from the National Medical Products Administration (NMPA) in China. The drug candidate is an anti-amyloid beta (Aβ) protofibril antibody that will be targeted as a treatment for mild cognitive impairment (MCI) due to Alzheimer's disease or mild Alzheimer's dementia.

BAN2401 is a humanized monoclonal antibody for Alzheimer’s disease that is the result of a strategic research alliance between Eisai and BioArctic. BAN2401 selectively binds to neutralize and eliminate soluble, toxic Aβ aggregates that are thought to contribute to the neurodegenerative process in Alzheimer’s disease.

An earlier Phase II trial for BAN2401 was thought to have failed at the 12-month stage (the initial cutoff point). However, its fortunes were revived when positive 18-month data showed that the 10 mg/kg dose led to significant reduction in disease progression at 18 months, and delayed clinical decline by 47%.


Reference:

Related news
China-based WuXi Biologics (2269.HK) announced that it a memorandum of understanding setting out the terms of a strategic partnership has been signed with Switzerland-headquartered AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company with a pipeline focused on neurodegenerative diseases.
U.S.-based, China-operating radiopharmaceutical and positron emission tomography (PET) specialist XingImaging LLC announced that the firm is offering PET imaging services in support of multi-center clinical trials targeting Alzheimer’s disease (AD) in China.
The China National Drug Administration (CNDA)’s Center for Drug Evaluation (CDE) unveiled a selection of 48 novel products already approved in the U.S., EU, or Japan that are in urgent clinical need in China and could be eligible for clinical trial waivers and moved directly to the market approval filing stage.
Recent news
Zoé Robledo Aburto, head of Mexico's Social Security Institute (IMSS), last week announced that the public institution will invest MXN 13 billion (USD 676 million) in 2020 as part of a program to complete over 111 new hospitals, 132 family clinics, 120 remodelings, and 200 additional infrastructure projects by the end of 2024.
Luiz Henrique Mandetta, head of Brazil’s Ministry of Health (MoH), last week discussed the Conecte SUS project, which aims to digitalize the Unified Health System (SUS) network, allowing public and private healthcare workers to access patients' clinical records from a centralized database.
GBI analysis shows that Argentina’s National Administration of Drugs, Food and Medical Technology (ANMAT) last week approved Monte Verde’s Vilzer (vildagliptin), a first-mover generic of Novartis’ hyperglycemia treatment Galvus/Glucemix/Zomarist​.
The Latin American Association of Pharmaceutical Industries (ALIFAR) shared with The Pharma Letter its plans for the current period of economic challenges and political changes.
  • 1574154772332
  • Argentina,Brazil,Mexico,Colombia,Peru,Venezuela,Chile,Uruguay,Paraguay,Ecuador ,Costa Rica,El Salvador,Bolivia ,Guatemala,Dominican Republic
  • Policy/Regulatory, Company
China-based Maider Medical Industry Equipment Co., Ltd announced that its initial public offering (IPO) will go ahead with the release of 20.9 million shares at RMB 24.79 (USD 3.53) per share on the Shanghai Science and Technology Innovation Board (STAR).
China-based China Grand Pharmaceutical and Healthcare Holdings Ltd (CGP; HK.512) announced it has entered into a licensing agreement with Australia’s Institution for Glycomics at Griffith University, focused on the latter’s first-in-class parainfluenza drug.
The Center for Drug Evaluation (CDE)’s website indicated that a clinical trial filing is currently under review in relation to pan fibroblast growth factor receptor (FGFR) inhibitor erdafitinib (Balversa), filed by Johnson & Johnson's China-based subsidiary Xian Janssen.
Analytics Snapshot


Analytics Snapshot